Literature DB >> 14611927

Lithium augmentation in venlafaxine non-responders: an open study.

G Bertschy1, E Ragama-Pardos, A Aït-Ameur, M Muscionico, S Favre, L Roth.   

Abstract

Thirteen major depressive patients not responding to a 4-week venlafaxine 300 mg treatment were eligible for a 4-week open trial of lithium addition. Two patients had to stop lithium for a possible moderate serotonin syndrome and five patients became responders, including one dramatic response and two semi-rapid responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14611927     DOI: 10.1016/j.eurpsy.2003.03.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  5 in total

1.  An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression.

Authors:  Jeremy Barowsky; Thomas L Schwartz
Journal:  Psychiatry (Edgmont)       Date:  2006-07

2.  Serotonin Syndrome following Introduction of Venlafaxine following Withdrawal of Phenelzine: Implications for Drug Washout Periods.

Authors:  Sarah J Yates; Niraj Ahuja; Sarah E Gartside; R Hamish McAllister-Williams
Journal:  Ther Adv Psychopharmacol       Date:  2011-08

3.  Time course of clinical response to venlafaxine: relevance of plasma level and chirality.

Authors:  Marianne Gex-Fabry; Androniki E Balant-Gorgia; Luc P Balant; Serge Rudaz; Jean-Luc Veuthey; Gilles Bertschy
Journal:  Eur J Clin Pharmacol       Date:  2003-12-24       Impact factor: 2.953

Review 4.  Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review.

Authors:  Alice Caldiroli; Enrico Capuzzi; Ilaria Tagliabue; Martina Capellazzi; Matteo Marcatili; Francesco Mucci; Fabrizia Colmegna; Massimo Clerici; Massimiliano Buoli; Antonios Dakanalis
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

5.  Combination/augmentation strategies for improving the treatment of depression.

Authors:  Chantal Moret
Journal:  Neuropsychiatr Dis Treat       Date:  2005-12       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.